Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis

Table 2

Comparison of therapeutic response rates in the studied groups using the intention-to-treat approach and per-protocol analysis.

Proportion (%) of patients with cure at 8 weeks
Analytical assumption^a	AmB group	GL group	OR (95% CI)	P
			(AmB versus GL)
Per protocol	22/39 (56.4)	25/37 (67.6)	1.610 (0.632, 4.101)	0.317
ITT	22/50 (44.0)	29/60 (48.3)	1.91 (0.560, 2.530)	0.650

GL: glucantime; AmB: liposomal amphotericin B; ITT: intention-to-treat; OR: odds ratio; CI: confidence interval.
^aPer protocol: analysis excluding patients that were lost to follow up, ITT: analysis including patients lost to follow up throughout the study, who were considered to have experienced treatment failure.